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INTRODUCTION 
Oral delivery of drugs is the most preferred route of drug 
delivery due to the ease of administration; low cost of 
therapy, patient compliance and flexibility in formulation 
etc.1 So the design of oral control drug delivery systems 
(DDS) should be primarily aimed to achieve more 
predictable and increased bioavailibility.2 Nowadays most 
of the pharmaceutical scientist is involved in developing 
the ideal drug delivery system. This ideal system should 
have advantage of single dose for the whole duration of 
treatment and it should deliver the active drug directly at 
the specific site. Scientists have succeeded to develop a 
system and it encourages the scientists to develop control 
release systems. Control release implies the predictability 
and reproducibility to control the drug release, drug 
concentration in target tissue and optimization of the 
therapeutic effect of a drug by controlling its release in the 
body with lower and less frequent dose.3, 4 It is widely 
acknowledged that the extent of GIT drug absorption is 
related to contact time with the intestinal mucosa. Thus, 
small intestinal transit time is an important parameter for 
drugs that are incompletely absorbed.5 Gastro retentive 
systems can continue to exist in the gastric region for 
several hours and hence prolong the period of gastric 
residence time (GRT) of drugs. The basic idea behind the 
development of such type of a system, to maintain a 
constant level of drug in the blood plasma inspire of the 
fact that the drug dose not undergoes disintegration by 
which drug usually keeps floating in the gastric fluid and 
slowly dissolves at a pre-determined rate to release the 
drug from the dosage form and maintain constant drug 
levels in the blood. Floating drug delivery systems 
(FDDS) are aimed to keep possession of the drug in the 
stomach and useful for poorly or unstable dosage form for 
those that are less or highly soluble and stable in intestinal 
fluids.6 It is the formulation of a drug and gel forming 
hydrocolloids meant to remain buoyant on stomach 
contents. This not only prolongs GI residence time but 
also does so in an area of the GI tract that would 
maximize drug reaching its absorption site in solution and 
hence ready for absorption.7 The principal is very simple 
that the floating of the drug in the stomach occurs due to 
the low density of the dosage form. Prolonged gastric 
retention time improves bioavailability, reduces wastage 
of the drug and improves solubility of those drugs which 
are less soluble at high pH. It has applications also for 
local drug delivery to the stomach and proximal small 
intestines. Gastro retention helps in improving 
bioavailability of new products with improved therapeutic 
possibilities and substantial benefits for patients. Based on 
these approaches, classification of floating drug delivery 
systems (FDDS) has been described in detail.8 
Basic Gastrointestinal Tract Physiology  
Basically stomach divided into 3 regions:   
1. Fundus: The fundus of the stomach is the left portion 
of the stomach's body, and is marked off from the 
remainder of the body by a plane passing horizontally 
through the cardiac orifice. The rounded part of the 
upper stomach allows for an accumulation of stomach 
gases produced by chemical digestion. 
2. Body: It also called the corpus and it is an anatomical 
region of the stomach in humans. 
3. Antrum (pylorus): The region of the stomach that 
connects to the duodenum is the pylorus. It has two 
parts, the pyloric antrum which connects to the body of 
the stomach, and the pyloric canal, which leads into 
the duodenum. 
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Figure 1 Physiology of Gastrointestinal Tract 
The proximal part made of fundus and body acts as a 
reservoir for undigested material, the antrum is the main 
site for mixing motions and act as a pump for gastric 
emptying by propelling actions.9 Gastric emptying occurs 
during fasting as well as fed states. The pattern of motility 
is however distinct in the two states. During the fasting 
state an inter-digestive series of electrical events take 
place, which cycle both through stomach and intestine 
every 2 to 3 hours.10 This is called the inter-digestive 
migrating myloelectric cycle (MMC). 
The inter-digestive migrating myloelectric cycle (MMC) 
is further divided into 4 phases as described by Wilson 
and Washington.11 
Phase I (basal phase) - lasts from 40 to 60 minutes with 
rare contractions. 
Phase II (preburst phase) - lasts for 40 to 60 minutes with 
intermittent action potential and contractions. As the 
phase progresses the intensity and frequency also 
increases gradually. 
Phase III (burst phase) - lasts for 4 to 6 minutes. It 
includes intense and regular contractions for short period. 
It is due to this wave that all the undigested material is 
swept out of the stomach down to the small intestine. It is 
also known as the housekeeper wave. 
Phase IV - lasts for 0 to 5 minutes and occur between 
phases III and I of 2 consecutive cycles. 
 
 
Figure 2: GI motility pattern
 
After the ingestion of a mixed meal, pattern of 
contractions changes from fasted state to fed state. This is 
also known as digestive motility pattern and comprises 
continuous contractions as in phase II of fasted state. 
These contractions result in reducing the food particle size 
(to less than 1 mm), which are propelled toward the 
pylorus in a suspension form. During the fed state, onset 
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of migrating myloelectric cycle (MMC) is delayed that 
results in slowing down of gastric emptying rate.1, 12 
Scintigraphic studies determine the gastric emptying rates 
allow to be seen that orally administered GRDFs are 
subjected to basically two complications, first short gastric 
residence time and second unpredictable gastric emptying 
rate. 
Classification of Floating Drug Delivery System
8 
A. Effervescent system 
 Gas generating system 
 Volatile liquid containing system 
B. Non-effervescent System: 
 Colloidal gel barrier system. 
 Alginate beds. 
 Hollow microspheres / Microballons. 
 Intragastric Floating Drug Delivery Device / 
Microporous compartment system 
Effervescent Floating Dosage Forms: 
These are matrix types of systems prepared with the help 
of swellable polymers (methylcellulose and chitosan) and 
various effervescent compounds (sodium bicarbonate, 
tartaric acid, and citric acid). They are formulated in such 
a way that when come in contact with acidic gastric 
contents, CO2 liberate and gas entrapped in swollen 
hydrocolloids which provides buoyancy to the dosage 
forms.13, 14 
Volatile liquid containing systems: 
The GRT of a drug delivery system can be sustained by 
incorporating an inflatable chamber, which contains a 
liquid (like ether, cyclopentane), that gasifies at body 
temperature to cause the inflatation of the chamber in the 
stomach. The device may also consist of a bio-erodible 
plug made up of PVA, Polyethylene, etc. that gradually 
dissolves and causing the inflatable chamber to release gas 
and collapse after a predetermined time to permit the 
spontaneous ejection of the inflatable systems from the 
stomach.15, 54 
Gas-generating Systems: 
These buoyant delivery systems utilize effervescent 
reactions between carbonate/bicarbonate salts and 
citric/tartaric acid to liberate CO2, which gets entrapped in 
the gellified hydrocolloid layer of the systems thus 
decreasing its specific gravity and making it to float over 
chyme.2, 55 
 
 
(a)                                          (b)          (c) 
Figure 3: Mechanism of floating of beads (GF=gastric fluid) 
Non-effervescent Floating Dosage Forms: 
The non-effervescent FDDS works on the mechanism of 
polymer swelling, bioadhesion of the polymer to mucosal 
layer of GI tract. The most commonly used excipients for 
the preparations of non-effervescent FDDS are gel 
forming or swellable cellulose type hydrocolloids, 
polysaccharides, and matrix-forming polymers like 
polycarbonate, polyacrylate, polymethacrylate, and 
polystyrene. The formulation method includes simple 
approach of thoroughly mixing of the drug and the gel-
forming hydrocolloid. After oral administration this 
dosage form swells in contact with gastric fluids and 
attains bulk density of less than 1. The air entrapped 
within the swollen matrix imparts buoyancy to the dosage 
form, so formed swollen gel-like structure acts as a 
reservoir and allows sustained release of drug through the 
gelatinous mass.13, 15, 16 
Colloidal gel barrier system: 
A system that contains drug with gel-forming 
hydrocolloids meant to remain buoyant on the stomach 
content. This prolongs GRT and maximizes the amount of 
drug that reaches its absorption sites in the solution form 
for ready absorption. This system incorporates a high level 
of one or more gel forming highly swellable cellulose type 
hydrocolloids.e.g. HEC, HPMC, NaCMC, 
Polysacchacarides and matrix forming polymer such as 
polycarbophil, polyacrylates and polystyrene, 
incorporated either in tablets or in capsule. On coming in 
contact with gastric fluid, the hydrocolloid in the system 
hydrates and forms a colloidal gel barrier around the gel 
surface. The air trapped by the swollen polymer maintains 
a density less than unity and confers buoyancy to this 
dosage forms.16, 54 
Alginate beads: 
Multi-unit floating dosage forms have been developed 
from freeze-dried calcium alginate. Spherical beads of 
approximately 2.5 mm in diameter can be prepared by 
dropping sodium alginate solution into aqueous solution 
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of calcium chloride, causing the precipitation of calcium 
alginate. The beads are then separated, snap-frozen in 
liquid nitrogen, and freeze-dried at -40ºC for 24 hours, 
leading to the formation of a porous system, which can 
maintain a floating force for over 12 hours.15, 16 
Hollow microspheres / Microballons: 
It is prepared by a novel emulsion solvent diffusion 
method. The ethanol/dichloromethane solution of the drug 
and an enteric acrylic polymer was poured into an agitated 
solution of Poly Vinyl Alcohol (PVA) that was thermally 
controlled at 40ºC. The gas phase is generated in the 
dispersed polymer droplet by the evaporation of 
dichloromethane formed and internal cavity in the 
microsphere of the polymer with drug.16, 17 
Intragastric / Microporous compartment system:
 
The system composed of a drug reservoir encapsulated in 
a microporous compartment having pores on top and 
bottom surfaces. The peripheral walls of the reservoir 
compartment were completely sealed to prevent any 
physical contact of the undissolved drug with walls of the 
stomach.17. 18 Novel levodopa gastro retentive dosage form 
based on unfolding polymeric membranes which 
combines extended dimensions with high rigidity. It was 
folded into a large size gelatin capsules. In vitro studies 
showed that unfolded form reached within 15 minutes 
after administration and it was confirmed in vivo in beagle 
dogs. The unfolded form was maintained for at least 2 
hours. It was concluded that this dosage form could 
improve therapy of different narrow absorption window 
drugs. However, there are possibilities of the polymeric 
films to get stuck in the esophagus causing extreme 
discomfort to the patient or drug related injuries and 
repeated administration of rigid dosage form may result in 
gastric obstruction.18, 19 
 
Figure 4: Intra-gastric floating drug delivery device 
 
Table 1: Some materials used for formulation of FDDS
 
S. No. Drugs Polymers used Ref 
1. Piroxicam Eudragit S 100 20 
2. Cefpodoxime Proxetil HPMC K15M, EC 21 
3. Furosemide HPMC 4000,HPMC 100, CMC, Sodium alginate, Xanthum gum 22 
4. Ketoprofen Eudragit RS and Eudragit RL 23 
5. Nimodipine HPMC, PEG-6000, Polaxamer-188 24 
6. Ciprofloxacin HPMC 25 
7. Para-amino benzoic acid Polyvinyl acetate, Purified shellac 26 
8. Paracetamol PVPK 30, Methyl Cellulose, HPMC (K4M,K15M,K100M) 27 
9. Cimetidine HPMC, Ethyl Cellulose 28 
10. Theophyline Methocel K100M, K15MCR 29 
11. Pentoxifilline  HPMC K4M, Sodium CMC, Ac-di-sol 30 
12. Verapamil Cellulose acetate, Eudragit S 100, Acrycoat A 100 31 
13. Celiprolol Hydrochloride HPMC (K4M,K15M,K100M), Ethyl Cellulose, Polyethylene oxide WSR-60K 32 
14. Metformin HPMC K4M and Ethyl Cellulose 33 
15. Stolol Hydrochloride Sodium carboxy methyl cellulose, Hydroxy propyl cellulose 34 
16. Famotidine Methocel K4M, K15M 35 
17. Cephalexine HPMC K4M, Xanthum gum, Guar gum, Microcrystalline cellulose 36 
18. Domperidone Maleate Xanthum gum, Methocel K4M, K15M, K100LV 37 
19. Glipizide Methocel K4M, Eudragit RS100 38 
20. Nimesulide HPMC of low and high viscosity, Guar gum, carbapol 39 
 
ADVANTAGES
 40, 41 
 Enhance Bioavailability 
 Sustained drug delivery 
 Reduce frequency of dosing 
 Targeted therapy of local ailments in the upper GIT 
 Reduce fluctuation of drug concentration 
 Minimize adverse activity colon 
DISADVANTAGES
42, 43 
 Not feasible for those drugs that have solubility or 
stability problems in gastric fluids 
 Not suitable for the drugs that are irritant to gastric 
mucosa 
 This system requires sufficient high level of fluids in 
stomach, so that the drug dosage form float therein and 
work efficiently 
 These systems also require the presence of food to 
delay their gastric emptying 
EVALUATION 
18, 28, 44-52 
Determination of the Drug Content: It provides how 
much amount of the drug that was present in the 
formulation and should not exceed the limits acquired by 
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the standard monographs. Drug content was determined 
by using spectroscopy techniques HPLC, HPTLC 
methods, Micro titrimetric methods, Inductively Coupled 
Plasma Atomic Emission Spectrometer, Near infrared 
spectroscopy. 
A. For Single Unit Dosage Forms (Tablet): 
 Floating lag time and total floating time: It is the 
time taken by the tablet to emerge on the surface of 
dissolution medium and expressed in few seconds or 
minutes. For determination of floating lag time and 
total floating time, simulated gastric fluid or 0.1 
mole.lit‐1 HCl (maintained at 370C) and USP 
dissolution apparatus containing 900 ml of 0.1 molar 
HCl as dissolution medium is used. 
 In-vitro drug release and floating duration: This is 
determined by using USP II apparatus (paddle) stirring 
on 50 or 100 rpm at 37 ± 0.2°c in simulated gastric 
fluid (pH 1.2 without pepsin). Aliquots of the samples 
are collected and analyzed for the drug content. The 
time (hrs) for which the tablets remain buoyant on the 
surface of the dissolution medium is the duration of 
floating and is visually observed. 
 In-vivo evaluation: This is carried out by means of X-
ray or Gamma scintigraphic monitoring of the dosage 
form transition in the GIT. 
 Content uniformity, hardness, friability: These tests 
are performed according to specified monographs. 
B. For Multiple Unit Dosage Forms (beads, 
Microspheres): 
Apart from the In vitro release, duration of floating and in 
vivo gastro-retention tests, the multiple unit dosage 
forms are also evaluated for – 
 Particle Size and shape: Dimensional and 
morphological analysis is carried out with the aid of 
scanning electron microscopy (SEM), and size can 
also be measured by optical microscope. 
 % yield of beads:  This is calculated from the 
following formula. 
(Weight obtained / Total weight of drug and polymer) 
×100 
 In vitro floating ability (Buoyancy %):  A known 
quantity of microspheres are spread over the surface of 
a USP (Type II) dissolution apparatus filled with 900 
ml of 0.1 N HCl containing 0.002% v/v Tween 80 and 
agitated at 100 rpm for 12 hours. After 12 hours, the 
floating and settled layers are separated, dried in a 
dessicator and weighed. The buoyancy is calculated 
from the following formula. 
{Wf / (Wf+Ws)} ×100 
Where Wf and Ws are the weights of floating 
microspheres and settled microspheres respectively. 
 Drug-excipient (DE) interactions: This is done using 
FTIR. Appearance of a new peak, and/or 
disappearance of original drug or excipient peak 
indicate the drug excipient interaction. Apart from the 
above mentioned evaluation parameters, granules are 
also evaluated for the effect of ageing with the help of 
Differential Scanning Calorimeter or Hot stage 
polarizing microscopy. 
 Swelling studies: This is performed to calculate 
molecular parameters of swollen polymers. It is 
determined by using Dissolution apparatus, optical 
microscopy and other sophisticated techniques which 
include Light scattering imaging (LSI), 
H1NMRimaging, Confocal laser scanning microscopy 
(CLSM), etc. By using Dissolution apparatus (USP 
dissolution apparatus (USP-24) labindia disso 2000) it 
is calculated as per the following formula. 
 
Swelling ratio = Weight of wet formulation / Weight of 
formulations 
 Entrapment efficiency:  The drug is extracted by a 
suitable method, analyzed and is calculated from the 
following formula. 
 
(Practical amount of drug present / Theoretical drug 
content) ×100 
 
APPLICATIONS OF FLOATING DRUG DELIVERY 
SYSTEMS: 
43, 54-55 
 Enhance bioavailability: The bioavailability of CR-
GRDF is significantly enhanced in comparison to the 
administration of non-GRDF CR polymeric 
formulations. There are several different processes, 
related to absorption and transit of the drug in the 
gastrointestinal tract, that act concomitantly to 
influence the magnitude of drug absorption. 
 Sustained drug delivery: Oral CR formulations are 
encountered with problems such as gastric residence 
time in the GIT. These problems can be overcome with 
the HBS systems which can remain in the stomach for 
long periods and have a bulk density <1 as a result of 
which they can float on the gastric contents.42 These 
systems are relatively larger in size and passing from 
the pyloric opening is prohibited.9, 55 
 Site–specific drug delivery systems: These systems 
are particularly advantageous for drugs those are 
specifically absorbed from the stomach or the 
proximal part of the small intestine.55 The controlled, 
slow delivery of drug to the stomach provides 
sufficient local therapeutic levels and limits the 
systemic exposure to the drug. It reduces the side 
effects which are caused by the drug in the blood 
circulation. In addition, the prolonged gastric 
availability from a site directed delivery system may 
also reduce the dosing frequency.  
 Absorption enhancement: Drugs which are having 
poor bioavailability because of site specific absorption 
from the upper part of the GIT are potential candidates 
to be formulated as floating drug delivery systems, 
there by maximizing their absorption.55 
 Minimize adverse activity at the colon: Retention of 
the drug in the HBS systems at the stomach minimizes 
the amount of drug that reaches the colon. Thus, 
undesirable activities of the drug in colon may be 
prevented. This pharmacodynamic aspect provides the 
rationale for GRDF formulation for beta-lactam 
antibiotics that are absorbed only from the small 
intestine, and whose presence in the colon leads to the 
development of microorganism’s resistance. 
 Reduce fluctuations of drug concentration: 
Continuous input of the drug following controlled 
release gastro-retentive dosage form administration 
produces blood drug concentrations within a narrower 
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range compared to the immediate release dosage 
forms. Thus, fluctuations in drug effects are minimized 
and concentration dependent adverse effects that are 
associated with peak concentrations can be prevented. 
This feature is of special importance for drugs with a 
narrow therapeutic index. 
CONCLUSION 
Drug absorption in the GIT is a highly variable procedure 
and prolonging GR of the dosage form extends the time 
for drug absorption. The FDDS become an additional 
advantage for drugs that are absorbed primarily in the 
upper part of GI tract, i.e., the stomach, duodenum, and 
jejunum. Floating drug delivery systems have emerged as 
an efficient means of enhancing the bioavailability 
controlled delivery of many drugs. FDDS promises to be a 
potential approach for gastric retention. Although there 
number of difficulties to be solved out to achieve 
prolonged gastric retention. Inspite of its various 
limitations serious efforts are being done to commercialize 
this delivery system. 
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